Florzolotau Tau PET for the prediction of clinical progression in the Shanghai Memory Study
AD core biomarkers are promising in improving clinical prognosis, among which quantitative tau burden is preferable to binary assessment, especially in the AD continuum.
Authors
- J. Wang
- Yi Guan (ORCID: https://orcid.org/0000-0002-5723-2756)
- Huiwei Zhang (ORCID: https://orcid.org/0000-0002-1509-2249)
- Jiaying Lu (ORCID: https://orcid.org/0000-0003-0927-0042)
- Tzu‐Chen Yen (ORCID: https://orcid.org/0000-0002-6136-0486)
- Qianhua Zhao
- Chao Zuo (ORCID: https://orcid.org/0000-0002-1461-0032)
- Huamei Lin
- Xiaoxi Ma (ORCID: https://orcid.org/0000-0001-7403-3700)
- Weiqi Bao
- Xiaowen Zhou
- Jie Wu (ORCID: https://orcid.org/0000-0003-4028-6173)
- Zizhao Ju
- Zhenxu Xiao
- Ming Li
- Ding Ding
Institutions
- Fudan University (CN)
- Io Therapeutics (United States) (US)
- Huashan Hospital (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70862_110028
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00